Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Alligator Bioscience AB ( (SE:ATORX) ) has provided an update.
Alligator Bioscience has completed a rights issue of units that was subscribed to about 64.8 percent, with approximately 61.2 percent taken up by existing shareholders through unit rights and 3.6 percent subscribed without rights, while guarantee commitments will cover around 9.1 percent of the issue. The transaction will initially raise roughly SEK 91 million before costs and loan repayments, significantly increasing the company’s share count and resulting in an estimated 91.2 percent dilution for existing shareholders, with the potential for a further dilution of about 31.3 percent if all associated TO 14 warrants are exercised in March 2026, which could bring in up to SEK 57 million more and materially extend the company’s funding but at a substantial ownership dilution.
More about Alligator Bioscience AB
Alligator Bioscience AB is a Swedish biotechnology company based in Lund that develops immuno-oncology drug candidates, focusing on antibody-based therapies aimed at treating cancer. The company is listed on Nasdaq Stockholm and finances its research and development activities through equity issues and related capital market instruments.
YTD Price Performance: -95.33%
Average Trading Volume: 4,440,952
Technical Sentiment Signal: Sell
Current Market Cap: SEK181.4M
For detailed information about ATORX stock, go to TipRanks’ Stock Analysis page.